DOI:
10.1055/s-00032260
Digestive Disease Interventions
LinksClose Window
References
Di Nicolantonio F, Martini M, Molinari F. , et al.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
J Clin Oncol 2008;
26 (35) 5705-5712
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.